Brilacidin is a small molecule host defense protein (HDP) mimetic with broad-spectrum antiviral and anti-inflammatory properties, potentially beneficial for COVID-19 by disrupting viral integrity and blocking viral entry via host cell heparan sulfate proteoglycans (HSPGs).
Jul 30 2021 |
, NCT04784897 | A Phase 2, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Evaluate the Efficacy and Safety of Brilacidin in Hospitalized Participants With COVID-19 |
| no change in mortality (p=1), 33% higher combined mortality/intubation (p=1), and 20% worse recovery (p=1). RCT 120 hospitalized COVID-19 patients showing no significant differences in pre-defined outcomes with brilacidin. | ||
Please send us corrections, updates, or comments.
c19early involves the extraction of 200,000+ datapoints from
thousands of papers. Community updates
help ensure high accuracy.
Treatments and other interventions are complementary.
All practical, effective, and safe
means should be used based on risk/benefit analysis.
No treatment or intervention is 100% available and effective for all current
and future variants.
We do not provide medical advice. Before taking any medication,
consult a qualified physician who can provide personalized advice and details
of risks and benefits based on your medical history and situation. IMA and WCH
provide treatment protocols.
Thanks for your feedback! Please search before submitting papers and note
that studies are listed under the date they were first available, which may be
the date of an earlier preprint.